Medications
Resources
Basic InformationLatest News
Brain Bleed Risk Puts Safety of Low-Dose Aspirin in DoubtAmericans' Prescription Med Use Is DecliningFDA Puts Tough Warning Label on Ambien, Lunesta, Other Sleep AidsDietary Supplements Do Nothing for You: StudyAre 'Inactive' Ingredients in Your Drugs Really So Harmless?Which Misused Prescription Meds Send Americans to the ER?Health Tip: What You Should Know About AntibioticsWhite House Plan to Disclose Drug Prices May Not Drive Down Costs: StudyWhen Your Medications Are the News1 in 4 Antibiotic Prescriptions Isn't Needed: StudyDermatologists Cut Back on Antibiotics But Still Prescribe the MostEven Older Drugs Are Getting Steep Price Hikes, Study FindsNew Cholesterol Drug's High Price May Not Be Worth It: StudyAre You Overdoing Antibiotics?Health Tip: Safe Tips For Antibiotic UseDrug Studies in Children Often Go Unfinished: StudyAmerica Is Worried About Antibiotic ResistanceMany U.S. Parents Share Leftover Antibiotics: SurveyFirst U.S. Drug Containing Marijuana-Derived Ingredient Goes on SaleGot Unused Prescription Meds? Saturday Is National Drug Take-Back DayAre Generics as Good as Brand-Name Drugs?White House Wants Prices in Drug Ads, But Big Pharma Fights BackHalf of Antibiotics Given Without Infection DiagnosisDoes Big Pharma Hike Prices When Meds Are in Short Supply?Timing May Be Critical When Taking MedsSurprising Tactic in War Against Antibiotic ResistanceOpium Poppy Genome Research May Aid Painkiller ProductionAs U.S. Kids Take More Meds, Dangerous Drug Mixes Could RiseHealth Tip: Grapefruit May Interact With MedicationFDA Slaps Stronger Warnings on Potent Class of AntibioticsTesting for Penicillin Allergy May Cut 'Superbug' Infection RiskAre Your Meds Making You Depressed?Health Tip: Packing Prescriptions for Travel
Questions and AnswersVideosLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Medical Disorders
Mental Disorders
Mental Health Professions

Does Big Pharma Hike Prices When Meds Are in Short Supply?

HealthDay News
by By Dennis ThompsonHealthDay Reporter
Updated: Sep 18th 2018

new article illustration

TUESDAY, Sept. 18, 2018 (HealthDay News) -- Pharmaceutical companies appear to be engaging in price gouging during drug shortages, with costs rising at double the normal rate when medications are in limited supply, a new study claims.

Prices can be expected to rise about 20 percent for drugs facing a shortage, but only about 9 percent for medicines in good supply, researchers report.

"It's clear the manufacturers are opportunistically pricing in a setting where they see a supply-and-demand mismatch," said senior researcher Dr. William Shrank. He is chief medical officer for the University of Pittsburgh Medical Center insurance services division.

The presence of competition tends to hold down price increases that occur during a shortage, the researchers also found.

Drugs made by three or fewer manufacturers can be expected to increase about 13 percent in price during a shortage, compared with just 8 percent price hikes during shortages affecting medicines supplied by more than three manufacturers, the study found.

"This effect was stronger in drugs that were supplied by three or less manufacturers," said lead researcher Inmaculada Hernandez, an assistant professor of pharmacy and therapeutics at the University of Pittsburgh School of Pharmacy.

For their study, the researchers drew data from the U.S. Food and Drug Administration's database on drug shortages.

The investigators identified 90 drugs that underwent an active shortage in 2016, and tracked pricing data for 11 months prior to and following each shortage, to see how prices were affected.

Prices of drugs increased by about 7 percent in the 11 months prior to a shortage, but about 16 percent in the 11 months after a shortage began, the findings showed.

Prices of drugs supplied by three or fewer manufacturers increased by 12 percent before and 27 percent following a shortage. For drugs supplied by more than three manufacturers, prices increased by 2.5 percent and 4.8 percent in the 11 months before and after the shortage began, respectively.

The findings were published online Sept. 17 in the Annals of Internal Medicine.

Pharmaceutical Research and Manufacturers of America (PhRMA) referred requests for comment to the Association for Accessible Medicines (AAM), a trade group for generic drug manufacturers.

The AAM said more recent events have overtaken this study, rendering its conclusions outdated.

"For the past two years since this study's short and dated snapshot in time, the generic industry has averaged 7 percent deflation of its prices," said Allen Goldberg, the AAM's vice president of communications. "We are working with government and industry to address the low reimbursement for generic drugs, which is the root cause of many shortages."

But the findings were "not surprising" to Claire McAndrew, director of campaigns and partnerships for Families USA, a health care consumer advocacy group.

"The results of this study are quantifying drug company behaviors we have witnessed during public health crises and drug shortages before," McAndrew said. "I think it's quite common that we see drug companies leveraging public health crises or drug shortages for huge profits."

As an example, McAndrew pointed to skyrocketing prices during the opioid epidemic for naloxone (Narcan), the lifesaving medicine that can reverse an opioid overdose.

"The entire drug pricing system right now is set up to allow profiting off of health crises, but there are steps policymakers can take related to the pricing system and the patent system to improve the way the system works for health care consumers," McAndrew explained.

Lawmakers could make it easier for generic versions of drugs to hit the market, improving price competition, McAndrew said. They also could craft other policies that discourage price gouging during shortages.

Shrank suggested that one tactic might be to cap the amount of price increase that can occur in the setting of a shortage.

"We could easily make an exception if there was some extenuating circumstance like a natural disaster," Shrank said. "In the absence of that, it seems reasonable to create a cap on drug prices during a shortage."

More information

The American Hospital Association has more about rising drug prices.




Facebook

Amazon Smile

To quit smoking, call Connecticut QuitLine at 1-800-QUIT-NOW.

Children and Adult services are available now with no wait time.  Please contact HBH Intake Department at 860-548-0101, option 2.

 


powered by centersite dot net